Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
Danvers, US
Size (employees)
747 (est)+27%
ABIOMED is headquartered in Danvers, US

ABIOMED Office Locations

ABIOMED has offices in Danvers and Aachen
Danvers, US (HQ)
22 Cherry Hill Dr
Aachen, DE
3 Neuenhofer Weg

ABIOMED Data and Metrics

ABIOMED Financial Metrics

ABIOMED's revenue was reported to be $329.5 m in 2016

Revenue (Y, 2016)

329.5 m

Revenue growth (Y, 2015 - Y, 2016), %


Net income (Y, 2016)

38.1 m

EBIT (Y, 2016)

65.1 m

Market capitalization (28-Jun-2017)

6.2 b

Closing share price (28-Jun-2017)


Cash (31-Mar-2016)

48.2 m
ABIOMED's current market capitalization is $6.2 b.
USDFY, 2014FY, 2015Y, 2016


183.6 m230.3 m329.5 m

Revenue growth, %


Gross profit

146.3 m190.4 m

Gross profit Margin, %


Operating expense total

138 m161.7 m264.4 m


8.4 m28.7 m65.1 m

EBIT margin, %


Pre tax profit

8.5 m28.8 m65.8 m

Income tax expense

1.2 m(84.9 m)27.7 m

Net Income

7.4 m113.7 m38.1 m
USDFY, 2014FY, 2015FY, 2016


20.9 m22.4 m48.2 m

Accounts Receivable

24.4 m31.8 m42.8 m


13.9 m16.8 m26.7 m

Current Assets

118 m220.1 m288.4 m


6.9 m9.1 m23.2 m


38 m31.5 m33 m

Total Assets

205.4 m338.4 m423.9 m

Accounts Payable

7.7 m10.4 m9.4 m

Current Liabilities

30.4 m39.3 m46.5 m

Additional Paid-in Capital

436.1 m465 m508.6 m

Retained Earnings

(250.9 m)(137.2 m)(99.1 m)

Total Equity

168.4 m291.6 m368.8 m

Financial Leverage

1.2 x1.2 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

7.4 m113.7 m38.1 m

Depreciation and Amortization

2.8 m3.3 m

Accounts Receivable

(1.3 m)(8 m)(11 m)


(622 k)(7 m)(11 m)

Accounts Payable

(54 k)3.4 m(2.6 m)

Cash From Operating Activities

23.5 m43.3 m76.8 m

Purchases of PP&E

(2.8 m)(5.2 m)(15.6 m)

Cash From Investing Activities

(22.3 m)(49.9 m)(57.7 m)

Cash From Financing Activities

9.6 m9.5 m7.2 m

Income Taxes Paid

1.3 m1.2 m848 k
Y, 2016

Financial Leverage

1.1 x

ABIOMED Market Value History

ABIOMED Median Salaries

Source: 15 public H-1B filings from ABIOMED

ABIOMED Online and Social Media Presence

ABIOMED News and Updates

ABIOMED Company Life and Culture

You may also be interested in